Thyroid Profiles in Patients With Acute Illness

Thyroid Profiles in Middle Eastern Patients Admitted With Acute Illness: Prevalence, Clinical Features and Impact on Mortality

Patients admitted to the hospital with acute illness may have a wide spectrum of thyroid function abnormalities. It is largely unknown whether such aberrations are temporary or persist for a long time, and whether they impact prognosis of such patients.

Study Overview

• Status: Withdrawn
• Conditions: Thyroid Dysfunction; Acute Illness
• Intervention / Treatment: Other: Performing blood thyroid test (TSH, FT4, FT3)

Detailed Description

Recently, there has been a growing body of evidence that subclinical thyroid dysfunction as a contributor to the increase of cardiovascular events. Elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine (FT4) and free triiodothyronine (FT3) levels have been associated with worse heart failure and dyslipidemia. Furthermore, higher risk of atrial fibrillation has been linked tp thyroid abnormalities in these patients.

Patients admitted to the hospital with acute illness may have a wide spectrum of thyroid function abnormalities. It is largely unknown whether such aberrations are temporary or persist for a long time, and whether they impact prognosis of such patients. This study aimed at evaluating the prevalence of thyroid function abnormalities in patients admitted to hospital with acute illness and their temporal changes and impact on mortality during hospitalization and at 1 year. Serum level of thyroid stimulating hormone and free T4 and T3 measured on admission. Clinical and laboratory profiles of patients with abnormal thyroid function (ATF group) will be compared to those with normal thyroid function (NTF group). Short and long term survival of both groups were compares as well.

• Study Type: Observational

Contacts and Locations

Study Locations

• Jordan
  • Amman, Jordan, 11888
    • Istishari Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

nclusion Criteria: All patients admitted to the hospital with acute illness will have their serum level of thyroid stimulating hormone and free T4 and T3 measured on admission. Clinical and laboratory profiles of patients with abnormal thyroid function (Group 1) will be compared to those with normal thyroid function (Group 2). Serum thyroid test will be repeated at 6 months. Short and long term survival of both groups will be compared as well.

Diagnosis on admission is acute illness includes: heart failure, acute coronary syndrome, sepsis, acute stroke, hypotension, acute system-organ failure including renal and hepatic failure.

Description

Inclusion Criteria:

• Hospital admission
• Adults aged 18 years and above
• Willing to sign an informed consent
• Diagnosis on admission is acute illness that includes: heart failure, acute coronary syndrome, sepsis, acute stroke, hypotension, acute system-organ failure including renal and hepatic failure.

Exclusion Criteria:

• Age less than 18 years.
• Refusal to sign consent.
• Admission for a reason not classified as acute illness.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
GROUP 1: Acute illness and abnormal thyroid function; Patients admitted to the hospital with acute illness and found to have thyroid function abnormalities.	Other: Performing blood thyroid test (TSH, FT4, FT3); Blood test as above
GROUP 2: Acute illness and normal thyroid function; Patients admitted to the hospital with acute illness and found to have normal thyroid function.	Other: Performing blood thyroid test (TSH, FT4, FT3); Blood test as above

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
In hospital mortality	All-cause death rate in patients with abnormal thyroid function compared with death in those with no abnormal thyroid function during the patients hospital stay..	From time of study entry until the date of death from any cause, assessed up to 2 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6-month mortality rate	All-cause death rate in patients with abnormal thyroid function compared with death in those with no abnormal thyroid function at 6 months.	From date of study entry until the date of death from any cause, assessed up to two weeks.

Collaborators and Investigators

• Sponsor: Jordan Collaborating Cardiology Group

Study record dates

Study Major Dates

• Study Start (Actual): October 15, 2023
• Primary Completion (Actual): January 15, 2025
• Study Completion (Actual): January 30, 2025

Study Registration Dates

• First Submitted: July 20, 2023
• First Submitted That Met QC Criteria: August 7, 2023
• First Posted (Actual): August 8, 2023

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 23, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: Prognosis; Acute illness; Thyroid abnormalities; Middle east
• Additional Relevant MeSH Terms: Endocrine System Diseases; Thyroid Diseases
• Other Study ID Numbers: DCR2023/1.ThyrAcuteIll

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Will contact other ICU physicians in the city of Amman to invite them to participate in the study

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No